



November 5, 2010

Steve Verheul  
Chief Trade Negotiator (Canada-European Union)  
Foreign Affairs and International Trade Canada  
111 Sussex Drive  
Ottawa, Ontario K1N 1J1

Subject: "Intellectual Property Issues in the Context of the CETA Negotiations between the Canada and the European Union"

Dear Mr. Verheul,

On behalf of the Japan Pharmaceutical Manufacturers Association (JPMA), I write to express our support for Canada-EU negotiations towards a Comprehensive Economic and Trade Agreement (CETA).

The JPMA is a voluntary association of over sixty research-oriented pharmaceutical companies in Japan. The JPMA is a member of the International Federation of Pharmaceutical Manufacturers & Associations and, in this capacity, is actively engaged on various global issues in the pharmaceutical and healthcare sector, including the development of innovative products to address emerging diseases across the globe and infectious diseases in developing countries, drug access problems, and intellectual property (IP) rights.

JPMA also works collaboratively with the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), Canada's Research-Based Pharmaceutical Companies (Rx&D), and other industry associations around the world on international harmonization of pharmaceutical regulations including through the International Conference on Harmonization.

We understand from JPMA members with operations in Canada that the CETA negotiations include proposals to strengthen and harmonize Canadian and EU IP standards applicable to biopharmaceutical products. We have also been specifically directed to the Canada-EU "Joint Report" on scoping for the CETA negotiations, which provides in particular as follows:

"The Scoping Group recognised that the WTO Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) sets minimum levels of protection for intellectual property (IP) rights, and was of the view that any EU-Canada agreement should substantially improve on all categories of IP rights where need for increased protection and/or enforcement is identified. Furthermore, any agreement should establish and/or maintain very high standards of protection and enforcement of IP rights."

From the perspective of the Japanese industry with operations in Canada, as well as from a more general trade and economic policy perspective, we are in full agreement with the above report by Canada and the EU.

Please accept the full support of JPMA on the CETA negotiations in this respect and let us know if there is anything the JPMA can do further to assist Canada and the EU to achieve successful and meaningful outcomes in this respect for the benefit of the research-based biopharmaceutical industry in Canada.

Sincerely yours,



Yasuchika Hasegawa  
President, Japan Pharmaceutical Manufacturers Association

Cc: Mauro Petriccione, EU Chief Negotiator, European Commission, DG Trade  
Russell Williams, President, Rx&D  
Andrew Witty, President, EFPIA  
Takihiro Hirasawa, President, Eisai Limited (Canada)  
Paul Friel, President & General Manager, Takeda Canada, Inc.  
Jonathan T. Fried, Ambassador of Canada to Japan